===============================================================================
                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549



                                    FORM 8-K

                                 CURRENT REPORT

                       Pursuant to Section 13 or 15(d) of
                       the Securities Exchange Act of 1934

                        Date of report (Date of earliest
                                event reported):
                                  June 24, 2009

                           HEMISPHERX BIOPHARMA, INC.
               (Exact Name of Registrant as Specified in Charter)

                           Delaware 0-27072 52-0845822
             (State or Other Jurisdiction (Commission (IRS Employer
               of Incorporation) File Number) Identification No.)

              1617 JFK Boulevard, Philadelphia, Pennsylvania, 19103
          (Address of Principal Executive Offices, including Zip Code)

       Registrant's telephone number, including area code: (215) 988-0080

                                 Not Applicable
          (Former Name or Former Address, if Changed Since Last Report)

     Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
           following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)

[ ] Soliciting  material  pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))

===============================================================================






Item 8.01 Other Events.

Our  Annual  Meeting of  Stockholders  was held on June 24,  2009.  As with last
year's meeting, there was an extremely low turnout. Even with the quorum lowered
to 40% for the meeting,  only  approximately  40.34 % of our outstanding  shares
voted. At the meeting, stockholders approved the following:

Election of Directors:

Nominees                               For                    Withheld

William A. Carter                   30,618,449                3,720,471
Richard C. Piani                    32,415,702                1,923,218
William M. Mitchell                 33,076,787                1,262,133
Iraj-Eqhbal Kiani, Ph.D.            32,532,815                1,806,105
Thomas K. Equels                    32,489,167                1,849,753

Ratification  of the  appointment of McGladrey & Pullen,  LLP as our independent
accountants:

For:  33,090,748           Against:  550,895         Abstain:  697,277.

Adoption of our 2009 Equity Incentive Plan:

For: 10,688,703            Against: 3,166,098        Abstain: 569,495.

We left  the  polls  opened  with  regard  to  voting  on the  amendment  of our
certificate of incorporation to increase the number of our authorized  shares of
Common Stock from  200,000,000 to  350,000,000  and adjourned the meeting solely
with  regard to this  proposal  until July 28,  2009 at 1:00 p.m. at the Embassy
Suites Hotel, 1776 Benjamin Franklin Parkway,  Philadelphia  Pennsylvania 19103.
We did this due to the  extremely  low vote  turn out and the  requirement  that
proposal be approved  by the  holders of a majority of the  outstanding  shares,
rather than just a majority of the shares present at the meeting.  Less than the
requisite  number of shares for  approval of the  proposal  were  present at the
meeting.

Total shares voted: 34,338,920 out of 85,130,832 eligible to vote.

For more  information,  please  see the June 24,  2009 press  released  filed as
exhibit 99.1 to this report.

Item 9.01.        Financial Statements and Exhibits.

              (c) Exhibits:

                 99.1  Press Release dated June 24, 2009




                                   Signatures

         Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the registrant has caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


Date:  June 24, 2009

                                                  HEMISPHERX BIOPHARMA, INC.


                                                   /s/ William A. Carter
                                                  __________________________
                                                  William A. Carter, M.D.,
                                                  Chief Executive Officer





                                                                    Exhibit 99.1


Dianne Will
Hemispherx Biopharma, Inc.
518-398-6222
ir@hemispherx.net

           Hemispherx Biopharma Reports on Annual Stockholder Meeting


PHILADELPHIA, PA--June 24, 2009--Hemispherx Biopharma (NYSE AMEX: HEB) announced
that it held its 2009 Annual Meeting of Stockholders.  Final voting results will
be included in an 8-K to be filed later today.

As with last year's Annual Meeting of  Stockholders,  there was an extremely low
turnout.  The Company  believes that this was due to the fact that more than 40%
of its  outstanding  shares are held  outside the United  States.  Most of these
shares are held at  European  banks that do not  participate  in the  proxies of
American  companies.  Even with the quorum lowered to 40% for the meeting,  only
approximately 40.34% of the outstanding shares entitled to vote were represented
in person or by proxy.

At the meeting,  each of the five  nominees for director  named in the Company's
proxy  statement  was elected to a one-year  term,  the selection of McGladrey &
Pullen, LLP as independent auditors for the fiscal year ending December 31, 2009
was ratified and the adoption of the Company's  2009 Equity  Incentive  Plan was
approved.

The Company left the polls opened with regard to voting on the  amendment of its
certificate  of  incorporation  to increase the number of  authorized  shares of
Common Stock from  200,000,000 to  350,000,000  and adjourned the meeting solely
with  regard to this  proposal  until July 28,  2009 at 1:00 p.m. at the Embassy
Suites Hotel, 1776 Benjamin Franklin Parkway,  Philadelphia  Pennsylvania 19103.
The Company did this due to the extremely low vote turn out and the  requirement
that this  proposal be approved by the holders of a majority of the  outstanding
shares,  rather than just a majority of the shares  present at the  meeting.  In
fact, less than the requisite number of shares for approval of the proposal were
present at the meeting.

About Hemispherx Biopharma
Hemispherx  Biopharma,  Inc.  is a  specialty  pharma  company  engaged  in  the
manufacture  and clinical  development  of new drug  entities  for  treatment of
seriously debilitating disorders. Hemispherx's flagship products include Alferon
N Injection(R)  (FDA approved for a category of sexually  transmitted  diseases)
and the  experimental  therapeutics,  Ampligen(R)  and Oragens.  Ampligen(R) and
Oragens  represent  experimental  RNA nucleic acids being developed for globally
important debilitating diseases and disorders of the immune system. Hemispherx's
platform  technology  includes  large and small agent  components  for potential
treatment  of  various  severely  debilitating  and life  threatening  diseases.
Hemispherx has in excess of 50 issued patents  comprising its core  intellectual
property estate and a fully commercialized product (Alferon N Injection(R)). The
Company  wholly  owns and  exclusively  operates a GMP  certified  manufacturing
facility in the United  States for  commercial  products.  For more  information
please visit www.hemispherx.net.

Information  contained in this news release other than  historical  information,
should be considered  forward-looking and is subject to various risk factors and
uncertainties. For instance, the strategies and operations of Hemispherx involve
risk of competition,  changing market conditions, change in laws and regulations
affecting these industries and numerous other factors  discussed in this release
and in the Company's  filings with the Securities and Exchange  Commission.  Any
specifically referenced investigational drugs and associated technologies of the
Company  (including  Ampligen(R),  Alferon LDO and Oragens) are  experimental in
nature  and as such  are not  designated  safe  and  effective  by a  regulatory
authority for general use and are legally available only through clinical trials
with the referenced  disorders.  The  forward-looking  statements  represent the
Company's  judgment  as of the  date of this  release.  The  Company  disclaims,
however,  any intent or obligation to update these  forward-looking  statements.
Clinical trials for other potential indications of the approved biologic Alferon
N Injection(R) do not imply that the product will ever be specifically  approved
commercially for these other treatment indications; similarly, the completion of
the NDA filing  process  with  Ampligen(R)  does not imply that the product will
ever be approved commercially.